Literature DB >> 3076122

Normal and pathological lipoprotein metabolism.

G R Thompson1.   

Abstract

Lipids are transported in plasma as lipoproteins, and an increase in 1 or more classes of lipoprotein underlies all forms of hyperlipidaemia. Physiological influences on lipoprotein metabolism are age, gender, bodyweight, diet and exercise. Pathological influences include genetic abnormalities, endocrine dysfunction, renal impairment and iatrogenic effects. Three inherited forms of hyperlipidaemia which predispose to atherosclerosis are familial hypercholesterolaemia (FH), type III hyperlipoproteinaemia and familial combined hyperlipidaemia (FCH), each of which has its own distinctive metabolism defect. In FH, deficiency of low density lipoprotein (LDL) receptors results in the accumulation in plasma of LDL-cholesterol because of a reduction in the receptor-mediated component of LDL catabolism. In type III hyperlipoproteinaemia, the presence of an abnormal apo E isoform (apo E2) in remnant particles leads to their accumulation in plasma, through nonrecognition by remnant receptors and a consequent reduced rate of hepatic uptake. In contrast, there is no primary catabolic defect in FCH, in which increased levels of very low density lipoprotein (VLDL) and LDL are largely the result of increased synthesis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3076122     DOI: 10.2165/00003495-198800363-00013

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  9 in total

Review 1.  Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study.

Authors:  W B Kannel; W P Castelli; T Gordon
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

Review 2.  Classification of hyperlipidaemias and hyperlipoproteinaemias.

Authors:  J L Beaumont; L A Carlson; G R Cooper; Z Fejfar; D S Fredrickson; T Strasser
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

Review 3.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-19       Impact factor: 91.245

4.  Familial hyper-alpha-lipoproteinemia: studies in eighteen kindreds.

Authors:  C J Glueck; R W Fallat; F Millett; P Gartside; R C Elston; R C Go
Journal:  Metabolism       Date:  1975-11       Impact factor: 8.694

5.  Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.

Authors:  J L Goldstein; H G Schrott; W R Hazzard; E L Bierman; A G Motulsky
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

Review 6.  Apolipoprotein E polymorphism in health and disease.

Authors:  G Utermann
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

Review 7.  Plasma lipoproteins: apolipoprotein structure and function.

Authors:  R W Mahley; T L Innerarity; S C Rall; K H Weisgraber
Journal:  J Lipid Res       Date:  1984-12-01       Impact factor: 5.922

8.  Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis.

Authors:  A D Sniderman; C Wolfson; B Teng; F A Franklin; P S Bachorik; P O Kwiterovich
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391

9.  The effects of age, body wight and family relationships on plasma lipoproteins and lipids in men, women and children of randomly selected families.

Authors:  S L Connor; W E Connor; G Sexton; L Calvin; S Bacon
Journal:  Circulation       Date:  1982-06       Impact factor: 29.690

  9 in total
  1 in total

Review 1.  Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Authors:  P Chrisp; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.